Author of

• 30601

  +

  P2.01 - Advanced NSCLC (ID 159)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 30668

    +

    P2.01-61 - Multiple Primary Carcinomas (MPC) in Patients with Non Small Cell Lung Cancer (NSCLC) (ID 914)

    10:15 - 18:15  |  Author(s): Kalliopi Athanasiadou
    • Abstract
    • Slides

    Background
    

    The improving survival of NSCLC patients, due to: 1. the initial diagnosis in early stages using the newer modern diagnostic tools, 2. the treatment of the disease with new effective antineoplastic drugs, and 3. the remarkable suspicion of the physicians, leads to registry of high incidence ratio of MPC in NSCLC patients.

    Method
    

    The aim of the study was the registration of the number and clinical characteristics of MPC in NSCLC patients. Between 4/1986-3/2019, 1756 patients, 1123 (64%)men, 633 (36%)women, median age 64(33-87)years and ECOG 2(0-3) were consequently admitted in our Unit. Stage <IIIA had 304(17%) and ≥IIIA 1452(83%)patients (groups A, B respectively). Median follow-up was 20+(1+-240+)months. Survival ≥5years observed in 351(20%)patients. According to our protocols, patients stage <IIIA, underwent only follow-up after radical surgery, while patients stage IIIA treated with platinum-based chemotherapy(PBC) adjuvantly or neoadjuvantly±locoregionally radiotherapy. Patients stage ≥IIIB received therapeutically PBC±radiotherapy.

    Result
    

    Eighty-six patients, 78/1123(7%)men, 8/633(1%)women (p<0.001), developed 102 MPC. The median interval time between NSCLC diagnosis and MPC detection, was 58(0-220)months. Two men experienced by four (all metachronous)MPC. One with lung adenocarcinoma(LADC), developed non-AIDS Kaposi-sarcoma of the leg, MDS and squamous-cell lung cancer(SqCLC). The second, with LADC, developed transitional-cell bladder carcinoma(TCBC), prostate adenocarcinoma(PrC), and colon cancer(CC). Five patients(3 men, 2 women) had by three, metachronous, MPC. One had LADC, NHL, CC, the second LADC, TCBC, PrC, and the third SqCLC, CLL and CC. One woman experienced LADC, lymphopenic HL and breast cancer(BC) and the other LADC, CLL, and small-cell lung carcinoma. Other 79 patients developed 79 MPC, 11(14%)median age 63(51-77)years, synchronous and 68(86%)median age 63.5(34-75)years, metachronous The synchronous were LADC/SqCLC in 2, LADC/PrC in 2, LADC/TCBC in 2, SqCLC/head-neck squamous-cell carcinoma(HNSqCC) in 2, and SqCLC/CC in 3 cases. The metachronous MPC were LADC, CLL, TCBC, SqCLC, PrC, CC, HNSqCC, BC, NHL, HL, in 12, 10, 8, 8, 8, 8, 6, 3, 3, 2, cases respectively. Among 351 patients surviving ≥5years, 40(11%) experienced MPC versus 46/1405(3%) with survival <5years(p <0.001). Seventy-five patients diagnosed with metachronous MPC: 10/304(3%) versus 65/1452(4.5%) of group A and B, (p=NS). There was no statistically significance in the location of non-haematological MPC related to the diaphragm (37 upper, 39 lower the diaphragm).

    Conclusion
    

    According to our findings in NSCLC patients: 1. MPC detection is not uncommon, mainly in men. 2. The longer survival enhances the possibility of MPC. This must be considered during the follow-up of those patients. 3. Previous chemoradiotherapy doesn’t increase the risk of MPC.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.